

IN THE CLAIMS

Please amend claims 43-48 and 58-61 as detailed below.

1.-22. (canceled)

23.-32. (withdrawn)

33.-38. (canceled)

39.-42. (withdrawn)

43. (currently amended) A binding composition comprising an antigen-binding site of an antibody that ~~which~~ specifically binds:

- a) a ~~mature~~ TECK polypeptide defined by the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4, or
- b) an antigenic fragment of the ~~mature~~ TECK polypeptide defined by the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4, or
- c) ~~a polypeptide that shares 45% sequence identity to the mature TECK polypeptide defined by the amino acid sequence set forth in SEQ ID NO: 4.~~

44. (currently amended) The binding composition of claim 43, wherein the binding composition is raised against a purified or recombinantly produced polypeptide comprising an eight contiguous amino acid fragment of the ~~mature~~ TECK polypeptide defined by the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4.

45. (currently amended) The binding composition of claim 43, wherein the binding composition is raised against a purified or recombinantly produced polypeptide comprising an antigenic fragment of the ~~mature~~ TECK polypeptide defined by the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4.

46. (currently amended) The binding composition of claim 43, wherein the binding composition is raised against a purified or recombinantly produced polypeptide comprising the ~~mature~~ TECK polypeptide defined by the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4.

47. (currently amended) The binding composition of claim 43, wherein the ~~mature~~ TECK polypeptide is denatured.

48. (currently amended) The binding composition of claim 43, wherein the ~~mature~~ TECK polypeptide is denatured by a detergent.

49. (previously presented) The binding composition of claim 43, wherein the binding composition is conjugated to a chemical moiety.

50. (previously presented) The binding composition of claim 43, wherein the binding composition is attached to a solid substrate.

51. (previously presented) The binding composition of claim 43, wherein the binding composition is detectably labeled.

52. (previously presented) The binding composition of claim 43, wherein the binding composition is a Fv fragment.

53. (previously presented) The binding composition of claim 43, wherein the binding composition is a Fab fragment.

54. (previously presented) The binding composition of claim 43, wherein the binding composition is a Fab2 fragment.
55. (previously presented) The binding composition of claim 43, wherein the binding composition is a monoclonal antibody.
56. (previously presented) The binding composition of claim 43, wherein the binding composition is a polyclonal antibody.
57. (previously presented) The binding composition of claim 43, wherein the binding composition is sterile.
58. (currently amended) The binding composition of claim 43, wherein the binding composition exhibits a K_d of at least ~~100 nM~~ 300 μ M to the ~~mature~~ TECK polypeptide.
59. (currently amended) The binding composition of claim 43, wherein the binding composition exhibits a K_d of greater than 30 ~~nM~~ μ M to the ~~mature~~ TECK polypeptide.
60. (currently amended) The binding composition of claim 43, wherein the binding composition exhibits a K_d of greater than 10 ~~nM~~ μ M to the ~~mature~~ TECK polypeptide.
61. (currently amended) The binding composition of claim 43, wherein the binding composition exhibits a K_d of greater than 3 ~~nM~~ μ M to the ~~mature~~ TECK polypeptide.
62. (previously presented) The binding composition of claim 43, wherein the binding composition inhibits TECK activity.
63. (previously presented) A kit comprising the binding composition of claim 43, wherein the kit further comprises:
a) instructional material for the binding composition or for disposal of reagents therein;
or
b) a container into which the binding composition is segregated.
64. (previously presented) A method for detecting a polypeptide in a sample, comprising:
a) contacting the sample with a binding composition of claim 43 under conditions to permit formation of a binding composition:polypeptide complex; and
b) detecting the complex.